Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference

NEW YORK, Aug. 5, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, August 13, 2013 at 9:45 a.m. ET. A live webcast of the company's presentation will be available on the "Events" section of Intercept's investor website at http://ir.interceptpharma.com. A replay of the presentation will also be archived and available on Intercept's website for 2 weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.

SOURCE Intercept Pharmaceuticals